America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that supports continued medical advances for patients. This includes small and large biopharmaceutical companies, academic researchers, government agencies, non-profit patient groups, clinical trial centers, health care providers, investors and of course patients.

Eli Lilly and Company’s chief medical officer, Dr. Tim Garnett, recently expanded on the U.S. R&D ecosystem in a new PhRMA video.